Compare FRPH & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | BBNX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 493.1M |
| IPO Year | 1995 | N/A |
| Metric | FRPH | BBNX |
|---|---|---|
| Price | $23.27 | $12.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 79.2K | ★ 624.6K |
| Earning Date | 04-10-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,846,000.00 | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | N/A | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $20.53 | $8.80 |
| 52 Week High | $27.98 | $32.71 |
| Indicator | FRPH | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 69.62 |
| Support Level | $23.10 | $12.71 |
| Resistance Level | $24.59 | $13.35 |
| Average True Range (ATR) | 0.70 | 0.74 |
| MACD | 0.12 | 0.35 |
| Stochastic Oscillator | 90.51 | 94.94 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.